A Phase 1 interventional study of Vitamin B-Complex Supplement in Optic Disc Edema and Endothelial Dysfunction, sponsored by National Aeronautics and Space Administration (NASA). Recruiting at 1 site in United States. Open to participants aged 20 Years to 100 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Aeronautics and Space Administration (NASA) · Phase 1, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Papilledema with a site in United States — 3 open to participants now, 3 under way, none of them phase 3. Papilledema · United States.
Among the 11 studies in Papilledema with a site in United States, this one is the only one that started in 2022, is one of 3 in phase 1, and was the 10th registered.
29 studies on the registry are indexed under Papilledema; 7 are open to participants now.
Browse Papilledema studies →3 of the 11 studies in Papilledema with a site in United States are open now. Recruiting first, the newest first:
Kovach Eye Institute · Sites in United States
Ages 18+
Brigham and Women's Hospital · Sites in United States
Ages 18–55
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 4 Papilledema studies recruiting now, 1 sets no upper age limit and 2 stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 20 Years to 100 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 4 · Phase 3 2 · Phase 4 1
First in 2003; this study’s year is marked. 1 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 16 is below the median of 50 across 19 interventional studies indexed under Papilledema.
Median enrollment 43 across the 9 interventional studies, 40 across the 2 observational. Of the 6 that completed or were terminated, 3 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 11 have an industry lead sponsor. The 10 most frequent:
National Aeronautics and Space Administration (NASA) is the lead sponsor of 14 studies on the registry; 5 are open to participants now.
National Aeronautics and Space Administration (NASA) has 1 study filed under Papilledema — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies in Papilledema with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
In this project, the investigators propose to test effectiveness of a daily nutraceutical supplement containing bioactive B vitamins to mitigate optic disc edema in astronauts. The proposed countermeasure is intended to maximize functioning of the one-carbon metabolic pathway to provide enough substrate and cofactors to overcome any genetic differences that may impact the efficiency of enzyme function. By optimizing the pathway, this will 1) optimize endothelial function by increasing eNOS coupling and nitric oxide synthesis and 2) optimize collagen firmness and elasticity in the sclera and lamina cribrosa, and 3) minimize changes in total retinal thickness during and after flight.
The protocol includes assessments of ocular health and function, along with determinants of vascular endothelial function, advanced glycation end products, and nutritional status and one carbon biochemistry. These additional measures will be critical for the further definition of the causes of optic disc edema in some astronauts after long-duration space flight, and in understanding the effect of the countermeasure. Finally, the supplemented subjects in this study will be compared against total retinal thickness data from previously flown astronauts known to have not taken supplements during their missions.
Fasting (8-h) blood samples (7.5 mL SST and 5 mL EDTA tubes, 12.5 mL total per session) will be collected approximately 180 days and 45 days before flight, and return to Earth +0-2 days and 30 days after landing.
Blood samples will be analyzed for vitamin status and one-carbon biochemistry, as previously described. One blood sample (collected before flight) will be analyzed for approximately 511 SNPs matching the profile of testing from our ongoing research related to optic disc edema. Serum samples will be analyzed for biochemistry measures evaluating endothelial function, vitamin status, and oxidative damage.
Nutritional status assessment data, including inflight dietary intake and body mass data, completed for routine medical requirements will be requested for data sharing. Inflight medical exercise log data as well as available standard measures data will also be requested for data sharing. Medication use/Med Logs will also be requested for data sharing.
Vascular function VENDYS-II (Endothelix, Inc) will be used to assess reactive hyperaemia through changes in fingertip temperature. The test consists of an automated blood pressure measurement followed by cuff occlusion of the right arm for 2 to 5 min. During this time, the fingertip temperature in the right hand decreases because of the lack of circulation in the fingertip. After the cuff is released, blood flow resumes, causing a temperature rebound in the fingertip in a manner that is proportional to vascular reactivity.
Advanced Glycation End (AGE) Products Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader (Diagnoptics Technologies, Groningen, the Netherlands). The AGE reader illuminates a skin surface of approximately 4 cm2, guarded against surrounding light, with an excitation light source with wavelength between 300 and 429 nm. This method is based on the fluorescent properties of certain AGEs accumulated in dermal tissue.
OCT and OCT-A Optical coherence tomography (OCT) and OCT-angiography (OCT-A) scans will be acquired using the Spectralis OCT2 (Heidelberg Engineering) before, during, and after flight. The scan pattern includes 24 B-scans centered in a radial pattern over the optic nerve head, as well as a 3.5 mm circle scan surrounding the optic nerve head for assessment of retinal nerve fiber layer thickness and choroid thickness. For OCT-A, five consecutive volume scans will be obtained in these regions, each containing 216 A-scans. These images will be registered, and the consecutive B-scans will be used to calculate the decorrelation among the images to provide split-spectrum amplitude decorrelation angiography (SSADA) images. This decorrelation between consecutive B-scan images will be used to highlight locations where there is blood flow. The density of the perfused peripapillary vessels within the various layers of the retina will be calculated to create a flow density map.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Subjects will take a vitamin B-complex supplement before, during, and after a 6-12 month spaceflight on the International Space Station
Drug: Vitamin B-Complex Supplement
Vitamin B-Complex Supplement containing: 5-methyltetrahydrofolate, riboflavin 5 phosphate, pyridoxal phosphate, and methylcobalamin
Optic Disc Edema
Measure change in total retinal thickness during and after flight compared to preflight using OCT
Time frame: 6 months
Endothelial function
Assess reactive hyperemia through changes in fingertip temperature
Time frame: 6 months
Advanced Glycation End Products (AGE)
Skin autofluorescence (SAF) will be analyzed non-invasively using an AGE reader
Time frame: 6 months
Serum folate status
Vitamin status assessed from a fasting blood sample
Time frame: 6 months
Red Blood Cell folate status
Vitamin status assessed from a fasting blood sample
Time frame: 6 months
Vitamin B6 status
Vitamin status assessed from a fasting blood sample
Time frame: 6 months
Vitamin B12 status
Vitamin status assessed from a fasting blood sample
Time frame: 6 months
Glucose
Serum glucose from a fasting blood sample
Time frame: 6 months
Nitric oxide
Serum nitric oxide from a fasting blood sample
Time frame: 6 months
tetrahydrobiopterin
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Dihydrobiopterin
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Oxidized glutathione
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Total antioxidant capacity
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Advanced glycation end products
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Albumin
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Glycated albumin
Serum biochemistry from a fasting blood sample
Time frame: 6 months
3-nitrotyrosine
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Formate
Serum biochemistry from a fasting blood sample
Time frame: 6 months
MMP-2
Serum biochemistry from a fasting blood sample
Time frame: 6 months
MMP-9
Serum biochemistry from a fasting blood sample
Time frame: 6 months
TIMP-1
Serum biochemistry from a fasting blood sample
Time frame: 6 months
TIMP-2
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Heparan sulfate
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Syndecan-1
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Glypican
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Hyaluronan
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Total lipid peroxides
Serum biochemistry from a fasting blood sample
Time frame: 6 months
Plan to share: No
Started Aug 2022 (actual). Primary completion is estimated for Jul 2032, 119 months after the start.
Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 12, 2026: primary completion Jul 2027 → Jul 2032 and completion Sep 2032 → Sep 2035.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Aeronautics and Space Administration (NASA)